$TLWR · Talawar Tx Inc.
Amendment No. 3 to Talawar Tx's S-4 registers the business combination with JATT II Acquisition Corp. JATT shareholders receive one Post-Closing Company share per JATT ordinary share. Talawar's transaction value is $120M (12M shares at $10.00), with a concurrent $225M PIPE of 22.5M shares at $10.00. The deal carries a related-party conflict: JATT CEO Dr. Someit Sidhu is also founder/CEO of Khanda Therapeutics, which licensed Talawar the assets it is developing, and is a significant Talawar stockholder.
- Transaction Share Consideration equals $120,000,000 divided by $10.00, implying 12M shares.
- PIPE investors committed $225,000,000 for 22.5M shares at $10.00 per share.
- Sponsor paid $25,000 for 1.725M Founder Shares (~$0.014/share); 150,000 more will be forfeited at Closing.
- Dr. Someit Sidhu recused himself from JATT board decisions on the Talawar deal due to conflicts.
- Up to $1,500,000 of Working Capital Loans may convert into Post-Closing shares at $10.00.
Price data unavailable.
A biotech de-SPAC with a $225M PIPE and a CEO with overlapping interests in both the target and the SPAC warrants close scrutiny.
A de-SPAC transaction in the biotech space (SIC 2836), with Talawar licensing assets from Khanda Therapeutics, a related party to JATT's CEO.
Material conflicts of interest exist between the Sponsor, JATT officers/directors, and Talawar officers/directors versus unaffiliated JATT shareholders. Redemption levels could reduce cash available to the Post-Closing Company.